Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Colorectal Neoplasms 12Rectal Neoplasms 5Colonic Neoplasms 5Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors (Excluding Breast Cancer) 2Advanced Solid Tumors 2Urologic Diseases 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Renal Insufficiency 1Refractory Solid Tumors 1Pretreated Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Kidney Diseases 1Head and Neck Neoplasms 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Biliary Tract Neoplasms 1Advanced or Metastatic Solid Tumors 1Advanced Gastrointestinal Tumors 1

Interventions

Temozolomide 6Cyclophosphamide 5Filgrastim 3Automobiles 3sargramostim 2fludarabine 2Thalidomide 2Magnetic Resonance Spectroscopy 2Etoposide 2Carmustine 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2veliparib 1trifluridine tipiracil drug combination 1trametinib 1thymoglobulin 1temsirolimus 1sonidegib 1ribociclib 1reolysin 1pegfilgrastim 1ibrutinib 1fludarabine phosphate 1entinostat 1carboxyamido-triazole 1azurin (50-77) 1aldesleukin 1Zoledronic Acid 1Vincristine 1Verteporfin 1Valproic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroectodermal Tumors, Primitive × trifluridine tipiracil drug combination × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡